Reply to: “Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer” and “Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails”-Reference-Cited by-同舟云学术

Reply to: “Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer” and “Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails”

Published:2024-07-05 Issue:3 Volume:116 Page:506-507
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Combarel David¹²^ORCID,Geraud Arthur³⁴,Gougis Paul⁵⁶⁷⁸^ORCID

Affiliation:

1. Pharmacology Department Gustave Roussy Villejuif France

2. Faculty of Pharmacy Paris‐Saclay University Chatenay‐Malabry France

3. Department of Medical Oncology Institut Paoli‐Calmettes Marseille France

4. Department of Cancer Medicine Gustave Roussy Villejuif France

5. Department of Pharmacology and Clinical Investigation Center (CIC‐1901) Pitié‐Salpêtrière Hospital, AP‐HP Sorbonne Université Paris France

6. INSERM, CIC‐1901 and UMR‐S 1166, Sorbonne Université Médecine Paris France

7. Oncology Department APHP‐Sorbonne Université, Cancer Institute (IUC) Paris France

8. Residual Tumor & Response to Treatment Laboratory, RT2Lab, INSERM, U932 Immunity and Cancer Curie Institute, Université Paris Paris France

Publisher

Wiley

Link

https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.3367

Reference6 articles.

1. Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer

2. Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails

3. Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use

4. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

5. Intra-patient variability in tacrolimus exposure: Causes, consequences for clinical management